VERA
Vera Therapeutics, Inc. (VERA) SWOT Analysis Analysis (2026)
Overall Score
Strengths
Strong liquidity with a current ratio of 10.9x and cash ratio of 1.01x.
Low leverage, with debt-to-equity at 0.18x and net debt to EBITDA near zero.
Net current asset value remains positive at $402.3M, supporting balance-sheet flexibility.
Weaknesses
Profitability remains deeply negative, with ROA at -75.4%, ROE at -84.1%, and ROIC at -85.8%.
Cash generation is weak, with free cash flow yield at -16.1% and operating cash flow yield at -7.0%.
Interest coverage is negative at -36.9x, reflecting ongoing operating losses.
Opportunities
If the company can convert its strong liquidity into operating improvement, the current cash position provides runway for execution.
The low enterprise value relative to cash and net current assets may offer upside if profitability stabilizes.
Threats
Persistent losses and negative cash flow could continue to pressure valuation and financing flexibility.
High cash conversion cycle and negative payables metrics suggest working-capital inefficiency remains a risk.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Vera Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

